Guohong Han

19.0k total citations · 2 hit papers
131 papers, 4.5k citations indexed

About

Guohong Han is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Guohong Han has authored 131 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Hepatology, 69 papers in Epidemiology and 52 papers in Surgery. Recurrent topics in Guohong Han's work include Liver Disease and Transplantation (73 papers), Liver Disease Diagnosis and Treatment (67 papers) and Hepatocellular Carcinoma Treatment and Prognosis (38 papers). Guohong Han is often cited by papers focused on Liver Disease and Transplantation (73 papers), Liver Disease Diagnosis and Treatment (67 papers) and Hepatocellular Carcinoma Treatment and Prognosis (38 papers). Guohong Han collaborates with scholars based in China, United States and Italy. Guohong Han's co-authors include Xingshun Qi, Daiming Fan, Ming Bai, Zhanxin Yin, Chuangye He, Zhiping Yang, Kaichun Wu, Jing Niu, Wengang Guo and Jijin Yang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Guohong Han

125 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

2016 479 citations Guohong Han, Gerold Meinhardt et al. Journal of Hepatology profile →
The role of hepatic resection in the treatment of hepatocellular cancer

2015 296 citations Guohong Han, Masatoshi Kudo et al. Hepatology profile →

Peers

Countries citing papers authored by Guohong Han

Since Specialization

Citations

This map shows the geographic impact of Guohong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guohong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guohong Han more than expected).

Fields of papers citing papers by Guohong Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guohong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guohong Han. The network helps show where Guohong Han may publish in the future.

Co-authorship network of co-authors of Guohong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Guohong Han. A scholar is included among the top collaborators of Guohong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guohong Han. Guohong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sorafenib combined with transarterial chemoembolization compared with sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial 2025 ·The Lancet Regional Health - Western Pacific ·Yan Zhao, Wei Bai, (unknown), Nan You, Lin Zheng, Lei Li, Jianbin Wu, Peng Zhang, Wukui Huang, Hui Zhang, Yongjin Zhang, (unknown), (unknown), (unknown), Daiming Fan, Yong Lv, Guohong Han	1
2	Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding 2024 ·Journal of Hepatology ·Yong Lv, Qiuhe Wang, Bohan Luo, Wei Bai, (unknown), Kai Li, Zhenyu Wang, Dongdong Xia, Wengang Guo, Xiaomei Li, Jie Yuan, Na Zhang, Xing Wang, Huahong Xie, Yanglin Pan, Yongzhan Nie, Zhanxin Yin, Daiming Fan, Guohong Han	5
3	TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis 2023 ·Journal of Hepatology ·Hélène Larrue, Gennaro D’Amico, Pol Olivas, Yong Lv, Theresa Bucsics, Marika Rudler, Tilman Sauerbruch, Virginia Hernández–Gea, Guohong Han, Thomas Reiberger, Dominique Thabut, Jean‐Pierre Vinel, Jean‐Marie Péron, Juan Carlos García‐Pagán, Christophe Bureau	47
4	Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis 2023 ·Hepatology ·Oana Nicoară-Farcău, Guohong Han, Marika Rudler, Debora Angrisani, Alberto Monescillo, Ferràn Torres, Georgina Casanovas, Jaime Bosch, Yong Lv, Philip D. Dunne, Peter Hayes, Dominique Thabut, Daiming Fan, Virginia Hernández–Gea, Juan Carlos García‐Pagán, (unknown)	16
5	Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial 2022 ·Hepatology ·Yong Lv, Hui Chen, Bohan Luo, Wei Bai, Kai Li, Zhengyu Wang, Dongdong Xia, Wengang Guo, Qiuhe Wang, Xiaomei Li, Jie Yuan, Hong Cai, Jielai Xia, Zhanxin Yin, Daiming Fan, Guohong Han	44
6	Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China 2022 ·Liver International ·Yong Lv, Daiming Fan, Guohong Han	10
7	Motor Cortex Mapping in Patients With Hepatic Myelopathy After Transjugular Intrahepatic Portosystemic Shunt 2018 ·Academic Radiology ·Long‐Biao Cui, (unknown), Yibin Xi, Ling‐Li Zeng, Gang Chen, Kang Liu, Tianlei Yu, Chuangye He, Wengang Guo, Zhanxin Yin, (unknown), Jing Niu, Bohan Luo, Dewen Hu, Guohong Han, Hong Yin	1
8	Image-guided treatment of Budd-Chiari syndrome: a giant leap from the past, a small step towards the future 2017 ·Abdominal Radiology ·(unknown), Guohong Han	2
9	Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment 2017 ·Annals of Oncology ·Jordi Bruix, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean–Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, (unknown), Annette Baumhauer, Gerold Meinhardt, Guohong Han	6
10	Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? 2017 ·CardioVascular and Interventional Radiology ·Yan Zhao, Rafael Durán, Wei Bai, Sonia Sahu, Wenjun Wang, Sven Kabus, MingDe Lin, Guohong Han, Jean-François Geschwind	24
11	Leg Ulcer in Budd-Chiari syndrome 2016 ·The American Journal of Gastroenterology ·Xingshun Qi, Guohong Han	3
12	The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization 2016 ·Scientific Reports ·Lei Liu, Yan Zhao, Jia Jia, Hui Chen, Wei Bai, Man Yang, Zhanxin Yin, Chuangye He, Lei Zhang, Wengang Guo, Jing Niu, Jie Yuan, Hong Cai, Jielai Xia, Daiming Fan, Guohong Han	37
13	Recurrent Budd-Chiari Syndrome Presenting with Lower Limb Ulcers 2015 ·Journal of Clinical and Experimental Hepatology ·Xingshun Qi, Kaichun Wu, Daiming Fan, Guohong Han	1
14	Imbalance of Pro- vs. Anti-Coagulation Factors in Chinese Patients with Budd-Chiari Syndrome and Non-Cirrhotic Portal Vein Thrombosis 2015 ·PLoS ONE ·Hui Chen, Lei Liu, Xingshun Qi, Chuangye He, Zhanxin Yin, Kaichun Wu, Daiming Fan, Guohong Han	4
15	The Prognostic Value of ¹⁸F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE) 2014 ·Theranostics ·Wenhui Ma, Jia Jia, Shengjun Wang, Wei Bai, Jingwei Yi, Ming Bai, (unknown), Zhanxin Yin, Daiming Fan, Jing Wang, Guohong Han	28
16	Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients 2013 ·Annals of Oncology ·Yan Zhao, (unknown), Sheng Guan, (unknown), (unknown), (unknown), (unknown), (unknown), Wei Bai, (unknown), Dongli Fan, (unknown), Guohong Han	90
17	Child-Na Score: A Predictive Model for Survival in Cirrhotic Patients with Symptomatic Portal Hypertension Treated with TIPS 2013 ·PLoS ONE ·Hui Chen, Ming Bai, Xingshun Qi, Lei Liu, Chuangye He, Zhanxin Yin, Daiming Fan, Guohong Han	11
18	Transjugular intrahepatic portosystemic shunt in the treatment of Budd–Chiari syndrome: a critical review of literatures 2013 ·Scandinavian Journal of Gastroenterology ·Xingshun Qi, Man Yang, Daiming Fan, Guohong Han	42
19	Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis 2012 ·Thrombosis Research ·Hui Chen, Xingshun Qi, Chuangye He, Zhanxin Yin, Daiming Fan, Guohong Han	31
20	Effect of Antithrombin, Protein C and Protein S on Portal Vein Thrombosis in Liver Cirrhosis: A Meta-analysis 2012 ·The American Journal of the Medical Sciences ·Xingshun Qi, (unknown), Guohong Han	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact